Following paricalcitol treatment of CKD explants, the increased basal Runx2 mRNA (p<0.001 compared to control artery) level was partially reduced (p<0.01), but still significantly higher than in respective control cultures (p<0.01). Here, RUNX2 is linked to chronic kidney disease.